Germany's New Health Law Introduces Automatic Price Cuts for New Drugs
Germany's proposed GKV savings law includes a new "catch-up solution" that mandates automatic price reductions for new medicines if reimbursement negotiations fail.
The German federal government is planning to introduce a new price-volume regulation mechanism within its proposed GKV (statutory health insurance) savings law (BStabG). This measure, termed a "catch-up solution," aims to automatically impose price reductions on new medicines if negotiations between pharmaceutical companies and the GKV fail to reach an agreement on reimbursement.
Industry stakeholders and experts have voiced strong opposition, characterizing the proposed mechanism as a "system break." They argue that it could jeopardize patient access to innovative therapies and negatively impact the investment environment for pharmaceutical research in Germany.
Currently, the prices for new drugs in Germany are determined through negotiations between pharmaceutical companies and the GKV. Existing legislation already requires these negotiations to consider volume-related aspects, such as volume discounts. If an agreement cannot be reached, a settlement committee decides the terms.
The German government, through the draft BStabG, suggests that the current negotiation outcomes are insufficient. The proposed "catch-up solution" would therefore apply an automatic, pre-defined formula for calculating discounts when agreement stalls, replacing the current case-by-case arbitration.
Dr. Andreas Heigl, head of health policy at Servier Deutschland, described the move as a "system break." He stated that while formal negotiations would still be possible, the new law would significantly strengthen the GKV's negotiating position, potentially reducing their incentive for genuine negotiation.